Publications by authors named "Hannah Kinoshita"
Article Synopsis
- CAR-T cell therapy is a promising treatment for a type of blood cancer called diffuse large B cell lymphoma (DLBCL), and there are 3 approved types targeting a specific protein (CD19).
- Even though it works well for many, about 60% of patients may still have issues or come back after treatment.
- Researchers are studying different reasons why some patients don't respond as well to CAR-T therapy, looking at things related to the patient, their cancer, and the treatment itself to help improve future outcomes.
Article Synopsis
- The study focuses on treating posttransplant lymphoproliferative disease (PTLD) in pediatric solid organ transplant recipients using rituximab and third-party T cells, aiming to combat Epstein-Barr virus-infected B cell proliferation due to weakened immune systems.
- Thirteen out of 15 patients received T cell therapy within 14 days, showing it was generally well tolerated, although there were some adverse effects like organ rejection and cytokine release syndrome.
- The results indicated a 70% overall response rate for newly diagnosed patients after the first treatment cycle, with a combined two-year survival rate of 70.7%, establishing the feasibility and potential benefits of this T cell therapy approach without chemotherapy.
Hematopoietic stem cell transplantation (HSCT) is being increasingly used as a curative approach for sickle cell disease (SCD). With the risk of graft-versus-host disease (GVHD), especially in the human leukocyte antigen-mismatched donors, intense immunosuppression is required leading to an increased risk of viral infection. Post-HSCT, adoptive transfer of virus-specific T-cell (VST) therapies have not been well-studied in patients with SCD.
View Article and Find Full Text PDFPatients with hematologic malignancies relapsing after allogeneic blood or marrow transplantation (BMT) have limited response to conventional salvage therapies, with an expected 1-year overall survival (OS) of <20%. We evaluated the safety and clinical outcomes following administration of a novel T-cell therapeutic targeting 3 tumor-associated antigens (TAA-T) in patients with acute leukemia who relapsed or were at high risk of relapse after allogeneic BMT. Lymphocytes obtained from the BMT donor were manufactured to target TAAs WT1, PRAME, and survivin, which are over-expressed and immunogenic in most hematologic malignancies.
View Article and Find Full Text PDFBackground: Despite similar rates of infection, adults and children have markedly different morbidity and mortality related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Compared to adults, children have infrequent severe manifestations of acute infection but are uniquely at risk for the rare and often severe Multisystem Inflammatory Syndrome in Children (MIS-C) following infection. We hypothesized that these differences in presentation are related to differences in the magnitude and/or antigen specificity of SARS-CoV-2-specific T cell (CST) responses between adults and children.
View Article and Find Full Text PDFImmunocompromised patients, including those with inborn errors of immunity (IEI), may be at increased risk for severe or prolonged infections with SARS-CoV-2 (Zhu et al. N Engl J Med. 382:727-33, 2020; Guan et al.
View Article and Find Full Text PDFCentral pontine myelinolysis (CPM) is rarely reported in pediatric patients with diabetic ketoacidosis (DKA). We report this case of a 16-year-old female with new onset diabetes presenting with DKA, who received aggressive fluid resuscitation and sodium bicarbonate in the emergency department. Later she developed altered mental status concerning for cerebral edema and received hyperosmolar therapy with only transient improvement.
View Article and Find Full Text PDFBackground: Placement of endotracheal tubes (ETTs) and umbilical catheters (UCs) is essential in very preterm infant care. The aim of this study was to assess the effect of an educational initiative to optimize correct placement of ETTs and UCs in very preterm infants.
Methods: A pre-post study design, evaluating optimal radiological position of ETTs and UCs in the first 72 h of life in infants <32 weeks gestational age (GA) was performed.